Literature DB >> 8195035

The role of DT-diaphorase in determining the sensitivity of human tumor cells to tirapazamine (SR 4233).

A V Patterson1, N Robertson, S Houlbrook, M A Stephens, G E Adams, A L Harris, I J Stratford, J Carmichael.   

Abstract

PURPOSE: To determine the dependency of the aerobic and hypoxic toxicity of tirapazamine on the intracellular activity of DT-diaphorase. METHODS AND MATERIALS: A panel of 18 human cell lines comprising predominantly small cell and nonsmall cell lung cancer and breast cancer lines were used. The activity of DT-diaphorase was determined in cytosolic preparations from cell lysates. The toxicity of tirapazamine was determined using the MTT assay after either 96 or 3 h aerobic exposure or 3 h treatment in hypoxia.
RESULTS: The cell lines exhibited a 5000-fold range in DT-diaphorase activity. In toxicity experiments, values of IC50 range from 10.2-120 microM and from 155-1230 for 96 and 3 h aerobic exposures, respectively. In N2, IC50s ranged from 8-55 microM. None of the toxicity values correlate with activity of DT-diaphorase, neither did the ratio of aerobic:hypoxic toxicity (differential toxicity).
CONCLUSION: The expression of DT-diaphorase in human tumor cells does not affect the toxicity of tirapazamine.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8195035     DOI: 10.1016/0360-3016(94)90291-7

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  9 in total

Review 1.  Enzymology of bioreductive drug activation.

Authors:  D Ross; H D Beall; D Siegel; R D Traver; D L Gustafson
Journal:  Br J Cancer Suppl       Date:  1996-07

2.  Induction of DT-diaphorase by 1,2-dithiole-3-thione and increase of antitumour activity of bioreductive agents.

Authors:  A Begleiter; M K Leith; T J Curphey
Journal:  Br J Cancer Suppl       Date:  1996-07

3.  Induction of DT-diaphorase by 1,2-dithiole-3-thiones in human tumour and normal cells and effect on anti-tumour activity of bioreductive agents.

Authors:  G P Doherty; M K Leith; X Wang; T J Curphey; A Begleiter
Journal:  Br J Cancer       Date:  1998-04       Impact factor: 7.640

4.  Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069.

Authors:  A V Patterson; M P Saunders; E C Chinje; D C Talbot; A L Harris; I J Strafford
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

5.  Systematic and Molecular Basis of the Antibacterial Action of Quinoxaline 1,4-Di-N-Oxides against Escherichia coli.

Authors:  Guyue Cheng; Bei Li; Chenxi Wang; Hongfei Zhang; Guixia Liang; Zhifei Weng; Haihong Hao; Xu Wang; Zhenli Liu; Menghong Dai; Yulian Wang; Zonghui Yuan
Journal:  PLoS One       Date:  2015-08-21       Impact factor: 3.240

6.  Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233).

Authors:  A V Patterson; H M Barham; E C Chinje; G E Adams; A L Harris; I J Stratford
Journal:  Br J Cancer       Date:  1995-11       Impact factor: 7.640

7.  NADPH:cytochrome c (P450) reductase activates tirapazamine (SR4233) to restore hypoxic and oxic cytotoxicity in an aerobic resistant derivative of the A549 lung cancer cell line.

Authors:  M P Saunders; A V Patterson; E C Chinje; A L Harris; I J Stratford
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

Review 8.  Quinoxaline 1,4-di-N-Oxides: Biological Activities and Mechanisms of Actions.

Authors:  Guyue Cheng; Wei Sa; Chen Cao; Liangliang Guo; Haihong Hao; Zhenli Liu; Xu Wang; Zonghui Yuan
Journal:  Front Pharmacol       Date:  2016-03-21       Impact factor: 5.810

Review 9.  Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs.

Authors:  Roger M Phillips
Journal:  Cancer Chemother Pharmacol       Date:  2016-01-25       Impact factor: 3.333

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.